NCT04560660View on ClinicalTrials.gov

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

July 1, 2025

Study Completion Date

October 7, 2025

Conditions
PTSD
Interventions
DRUG

Ketamine

FDA approved anesthetic medication with rapid acting antidepressant effects.

DRUG

Midazolam

FDA approved sedative medication with dissociative effects.

Trial Locations (1)

55417-2309

Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT04560660 - Ketamine-enhanced Prolonged Exposure Therapy in PTSD | Biotech Hunter | Biotech Hunter